Xiaodong Cheng

The Expression and Clinical Significance of C1orf106 in Low‐Grade Serous Ovarian Cancer

ABSTRACT Aim Low‐grade serous ovarian cancer (LGSOC) is a rare subtype of ovarian cancer with distinct biological behavior. This study aimed to identify new biomarkers with potential diagnostic and prognostic value for LGSOC. Methods Gene‐expression data were downloaded from the Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were identified using R. Functional enrichment analyses were conducted to determine the biological functions and signaling pathways associated with DEGs. The mitogen‐activated protein kinase (MAPK) pathway‐related gene, chromosome 1 open reading frame 106 ( C1orf106 ), was selected as the target gene. Immunohistochemistry and quantitative real‐time polymerase chain reaction (qRT‐PCR) were performed to verify its expression. Associations between C1orf106 expression and the clinical features of patients were analyzed using the chi‐square ( χ 2 ) test. Prognostic significance was evaluated with survival analyses. Results A total of 3099 upregulated and 4968 downregulated genes were identified in LGSOC. Gene set enrichment analysis (GSEA) demonstrated significant alterations in KRAS signaling and metabolic pathways between LGSOC and healthy controls. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses revealed enrichment in immune response and MAPK pathway alterations. Immunohistochemistry and qRT‐PCR confirmed that C1orf106 expression in LGSOC tissues was significantly higher than in normal ovarian tissues. Clinically, high C1orf106 expression was associated with lower BMI (< 25 kg/m 2 ), the absence of visible residual disease, and improved progression‐free survival (PFS) and overall survival (OS) in univariate Cox and Kaplan–Meier analyses. Conclusions C1orf106 may serve as a promising marker for the diagnosis and prognosis of LGSOC.

A Predictive Model for Initial Platinum‐Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue‐Derived Small Extracellular Vesicles

AbstractEpithelial ovarian cancer (EOC) is an often‐fatal malignancy marked by the development of resistance to platinum‐based chemotherapy. Thus, accurate prediction of platinum drug efficacy is crucial for strategically selecting postoperative interventions to mitigate the risks associated with suboptimal therapeutic outcomes and adverse effects. Tissue‐derived extracellular vesicles (tsEVs), in contrast to their plasma counterparts, have emerged as a powerful tool for examining distinctive attributes of EOC tissues. In this study, 4D data‐independent acquisition (DIA) proteomic sequencing was performed on tsEVs obtained from 58 platinum‐sensitive and 30 platinum‐resistant patients with EOC. The analysis revealed a notable enrichment of differentially expressed proteins that were predominantly associated with immune‐related pathways. Moreover, pivotal immune‐related proteins (IRPs) were identified by LASSO regression. These factors, combined with clinical parameters selected through univariate logistic regression, were used for the construction of a model employing multivariate logistic regression. This model integrated three tsEV IRPs, CCR1, IGHV_35 and CD72, with one clinical parameter, the presence of postoperative residual lesions. Thus, this model could predict the efficacy of initial platinum‐based chemotherapy in patients with EOC post‐surgery, providing prognostic insights even before the initiation of chemotherapy.

The distribution of colposcopy directed ectocervical biopsy and endocervical curettage results: a retrospective study of 47,134 cases

To investigate the distribution of colposcopy directed ectocervical biopsy and endocervical curettage (ECC) results, and to identify patients who may benefit from ECC. This retrospective study analyzed the clinical data of 47,134 patients who underwent colposcopy directed ectocervical biopsy and ECC between January 2021 and December 2023. Risk factors were identified by univariate and multivariate logistic analyses. The positive rate of the final histopathological diagnosis was 37.1% (17,503/47,134), with 22.8% (10,724/47,134) for low-grade squamous intraepithelial lesion (LSIL) and 14.4% (6,779/47,134) for high-grade squamous intraepithelial lesion (HSIL) or worse lesions (≥HSIL). At final diagnosis of LSIL, HSIL, adenocarcinoma ECC is a useful procedure for detecting additional endocervical lesions, and is recommended for patients aged ≥ 45, with high-risk HPV infection, ASC-H + or AGC cytology, and TZ3, as it will help reduce the rate of missed diagnosis of cervical lesions.

Analysis of follow-up outcomes in patients with cervical histologic low-grade squamous intraepithelial lesion preceded by serious cytology and repeated diagnosis for at least 2 years

Background: Treatment protocol for patients with cervical histologic low-grade squamous intraepithelial lesion (LSIL) such as that preceded by serious cytology and repeated diagnosis for at least 2 years is unclear. Objective: This study investigates the follow-up results of patients with cervical histologic LSIL and aims to provide evidence support for treatment and follow-up strategy. Design: A retrospective observational study design was used. Methods: The retrospective study included 4263 patients with cervical histologic LSIL diagnosed between August 2014 and February 2021. The follow-up period ended in August 2023. Results: During the followed-up of 6–101 months, 3246 (76.1%), 628 (14.7%), and 389 (9.1%) of the 4263 patients had lesion regression, persistence, and progression. Multiple gravidities, high-risk human papillomavirus (HPV) positive, HPV 16 positive, and cytologic examination (⩾atypical squamous cells cannot exclude high grade squamous intraepithelial lesion (ASC-H)) were independent risk factors for histologic LSIL progression. The annual cumulative cervical intraepithelial neoplasia (CIN)3+ rate of patients with histologic LSIL preceded by cytologic ASC-H and gravidity >2 was 6.3% (1-year), 22.4% (2-year), 28.2% (3-year), 28.2% (4-year), and 28.2% (5-year). The cumulative CIN2+ and CIN3+ rates in patients with histologic LSIL under risk factors and repeated diagnosis for at least 2 years were significantly higher than patients preceded by cytologic negative for intraepithelial lesion or malignancy, atypical squamous cells of undetermined significance, and LSIL. Conclusion: Cervical histologic LSIL had a high natural regression rate and a low progression rate. Multiple gravidities, high-risk HPV positivity, HPV 16 positivity, and cytological examination ⩾ASC-H were risk factors for histologic LSIL progression. For patients with histologic LSIL preceded by cytologic ASC-H, stratified management based on the number of gravidities might be an option.

Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study

To evaluate the impact of bleomycin/etoposide/cisplatin (BEP) and paclitaxel/carboplatin (PC) chemotherapy regimens on the fertility and prognostic outcomes in malignant ovarian germ cell tumor (MOGCT) patients who underwent fertility-sparing surgery (FSS). A propensity score matching algorithm was performed between the BEP and PC groups. The χ² test and the Kaplan-Meier method were used to compare the fertility outcome, disease-free survival (DFS) and overall survival (OS). The Cox proportional hazards regression analysis was used to identify risk factor of DFS. We included 213 patients, 185 (86.9%) underwent BEP chemotherapy, and 28 (13.1%) underwent PC chemotherapy. The median age was 22 years (range, 8-44 years), and the median follow-up period was 63 months (range, 2-191 months). Fifty-one (29.3%) patients had a pregnancy plan, and 35 (85.4%) delivered successfully. In the before and after propensity score matching cohorts, there were no significant differences in spontaneous abortion, selective termination of pregnancy, during-pregnancy status, and live birth between the BEP and PC groups (p>0.05). Fourteen (6.6%) patients experienced recurrence, including 11 (5.9%) in the BEP group and 3 (10.7%) in the PC group. Four (1.9%) patients in the BEP group died. Kaplan-Meier analysis revealed no significant differences in DFS (p=0.328) and OS (p=0.446) between the BEP and PC groups, and the same survival results were observed in the after matching cohort. The PC regimen is as safe as the BEP regimen for MOGCT patients with fertility preservation treatment, and no differences were observed in fertility and clinical prognosis.

A Nomogram for Predicting Cancer-Specific Survival in Patients With Stage I Vulvar Squamous Cell Carcinoma: A Study Based on the SEER Database and External Validation

Introduction Vulvar squamous cell carcinoma (VSCC) is a rare but increasingly prevalent gynecological malignancy. This study aimed to identify risk factors for stage I VSCC, which accounts for approximately 70% of VSCC patients, and to develop a nomogram to predict cancer-specific survival (CSS) for this large subgroup. Methods This study analyzed the datasets consisting of public training and independent external validation sets of patients diagnosed with stage I VSCC between 2010 and 2019. Prognostic factors were discerned through Cox regression analyses and the least absolute shrinkage and selection operator (LASSO) method. A nomogram for CSS was developed and evaluated using the C-index, Kaplan-Meier curves, and decision curve analysis (DCA) plots. Results Our analysis revealed variations in predictors of CSS and overall survival (OS) in stage I VSCC cases from the Surveillance, Epidemiology, and End Results (SEER) database. The multivariate Cox model suggested associations between CSS and age, grade, and number of tumors (NMT), while the LASSO model indicated potential roles for age, stage, invasion depth, NMT, and surgical method. The nomogram showed reasonable discriminative ability in the training (C-index: 0.785) and validation cohorts (C-index: 0.729), with supporting Kaplan-Meier and DCA analyses. Conclusion This study proposes a prognostic model for CSS in stage I VSCC, identifying exploratory associations with multifocal tumors and surgical extent. Further prospective studies are needed to validate these findings and clarify their clinical implications.